The centre will be funded by the Engineering and Physical Sciences Research Council (EPSRC), the Biotechnology and Biological Sciences Research (BBSRC) and the Technology Strategy Board.
Having supported Imperial College's application, the BioIndustry Association (BIA) welcomes today's announcement.
SynbiCITE will develop a collaborative network which will help to realise the true value and potential of synthetic biology by bringing together researchers from 18 academic organisations and 13 industrial partners, bolstering the UK's position as a world-leading location for science
The centre will focus on the commercialisation and application of promising science and technology. Emerging companies in the synthetic biology field, such as those that have recently joined the BIA's Synthetic Biology Advisory Committee, will stand to benefit from the centre's support and expert knowledge as they reach commercial maturity.
Steve Bates, BIA Chief Executive Officer, said:
"We welcome the decision to establish SynbiCITE at Imperial College and we look forward to working with them on this exciting project to develop a centre of national importance. The BIA is uniquely positioned to help them engage with both business and the public as the sector works to develop responsible innovation in synthetic biology."
Dr Tim Fell, CEO of synthetic biology company Synthace and Chair of the BIA's Synthetic Biology Advisory Committee, said:
"SynbiCITE establishes exactly the type of knowledge-rich environment that is highly conducive for small companies seeking to collaborate with academics and other businesses. This is welcome news of direct commercial relevance which further strengthens the UK's world class synthetic biology community."